União Europeia - holandês - EMA (European Medicines Agency)

vetcare oy - medetomidine hydrochloride, vatinoxan hydrochloride - psycholeptica, hypnotica en kalmerende middelen - honden - to provide restraint, sedation and analgesia during conduct of non-invasive, non-painful or mildly painful procedures and examinations intended to last no more than 30 minutes.

União Europeia - holandês - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastische middelen - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. zie rubriek 5 voor meer informatie over de status van humane epidermale groeifactorreceptor 2 (her2). vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. raadpleeg sectie 5 voor meer informatie over her2-status. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

União Europeia - holandês - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - telmisartan - hypertensie - cardiovasculair systeem - behandeling van essentiële hypertensie bij volwassenen:toevoegen op therapyonduarp is geïndiceerd bij volwassenen wier bloeddruk niet voldoende onder controle is met amlodipine. vervanging therapyadult patiënten die met telmisartan en amlodipine van afzonderlijke tabletten kunnen in plaats daarvan verschijnt tabletten van onduarp met dezelfde component doses.

União Europeia - holandês - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren, amlodipine, hydrochloorthiazide - hypertensie - cardiovasculair systeem - rasitrio is geïndiceerd voor de behandeling van essentiële hypertensie als substitutietherapie bij volwassen patiënten wiens bloeddruk afdoende wordt beheerst op de combinatie van aliskiren amlodipine, hydrochloorthiazide gegeven gelijktijdig op dezelfde dosisniveaus niveau als in de combinatie.

União Europeia - holandês - EMA (European Medicines Agency)

genzyme europe bv - mipomersen natrium - hypercholesterolemie - cardiovasculair systeem - behandeling van cholesterol en een verhoogd cholesterolgehalte,.

Bélgica - holandês - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

reckitt benckiser (healthcare) sa-nv - ibuprofen 200 mg/5 ml - suspensie voor oraal gebruik - 4 % - ibuprofen 40 mg/ml - ibuprofen

Bélgica - holandês - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

reckitt benckiser (healthcare) sa-nv - ibuprofen 200 mg/5 ml - suspensie voor oraal gebruik - 4 % - ibuprofen 40 mg/ml - ibuprofen

Holanda - holandês - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

reckitt benckiser healthcare b.v. siriusdreef 14 2132 wt hoofddorp - ibuprofen 40 mg/ml - suspensie voor oraal gebruik - aardbeiensmaakstof ; ascorbinezuur (l-) (e 300) ; citroenzuur 1-water (e 330) ; domifeenbromide ; glycerol (e 422) ; maltitol, vloeibaar (e 965) ; natriumchloride ; polysorbaat 80 (e 433) ; propyleenglycol (e 1520) ; saccharoide natrium x-water (e 954) ; trinatriumcitraat 2-water (e 331) ; water, gezuiverd ; xanthaangom (e 415), - ibuprofen

Holanda - holandês - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

reckitt benckiser healthcare b.v. siriusdreef 14 2132 wt hoofddorp - ibuprofen 40 mg/ml - suspensie voor oraal gebruik - arabische gom (e 414) ; citroenzuur 1-water (e 330) ; domifeenbromide ; glycerol (e 422) ; maltitol, vloeibaar (e 965) ; maltodextrine ; maÏszetmeel, gemodificeerd (modificatie onbekend ; natriumchloride ; polysorbaat 80 (e 433) ; saccharoide natrium x-water (e 954) ; sinaasappelsmaakstof ; trinatriumcitraat 2-water (e 331) ; water, gezuiverd ; xanthaangom (e 415), arabische gom (e 414) ; citroenzuur 1-water (e 330) ; domifeenbromide ; glycerol (e 422) ; maltitol, vloeibaar (e 965) ; maltodextrine ; maÏszetmeel, gemodificeerd (modificatie onbekend, (e 1450) ; natriumchloride ; polysorbaat 80 (e 433) ; saccharoide natrium x-water (e 954) ; sinaasappelsmaakstof ; trinatriumcitraat 2-water (e 331) ; water, gezuiverd ; xanthaangom (e 415), - ibuprofen

Bélgica - holandês - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

xeolas pharmaceuticals ltd. - omeprazol 180 mg - poeder voor suspensie voor oraal gebruik - omeprazole